tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight ๐ซ4th ACC.25 Congress Coverage: Tirzepatide
Pay in 4 interest-free payments of $6.18 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 23 - Aug 28
![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight 4th ACC.25 Congress Coverage: Tirzepatide](https://cdn.sanity.io/images/0vv8moc6/patientcare/316a4db2c4f4ca4cd65d61f557880d0739bd6544-630x445.jpg)
![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight 4th ACC.25 Congress Coverage: Tirzepatide](https://d14d5nk8lue86f.cloudfront.net/s3fs-public/2025-02/e9c84c10-d166-4f6d-8f89-af229288169f.png)
![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight 4th ACC.25 Congress Coverage: Tirzepatide](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/ac1a6655788bd234bf64c21c4a5867bfd3f189e9-6799x4532.jpg)
![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight 4th ACC.25 Congress Coverage: Tirzepatide](https://i.ytimg.com/vi/P4vGU1eUF9Y/maxresdefault.jpg)
![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight 4th ACC.25 Congress Coverage: Tirzepatide](https://www.acc.org/-/media/Non-Clinical/Images/Latest-in-Cardiology/Articles/2024/11/W24012-SUMMIT-AHA-2024-Visual-Abstract.png)

%201600x800.webp)





















